Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic tests endoscopic GERD (gastroesophageal reflux disease) therapy in US trial:

This article was originally published in Clinica

Executive Summary

Medtronic has started a pivotal US trial of its endoscopic treatment for gastroesophageal reflux disease (GERD), a condition that affects 21 million Americans. The Gatekeeper reflux repair system, already approved in Europe, is designed to reduce the symptoms associated with GERD through the use of prostheses that mimic the normal functioning barrier between the stomach and the oesophagus. The US trial will include 144 patients. Importantly, Medtronic says, it is the first clinical trial of an endoscopic therapy to treat GERD that will measure the placebo effect before the product is submitted to the FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel